Orforglipron to lower cardiovascular events in adults with atherosclerotic cardiovascular disease or chronic kidney disease (ATTAIN-Outcomes)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3, randomized, placebo-controlled study compares orforglipron with placebo in adults who have established ASCVD and/or CKD. Participants will be assigned to receive orforglipron or matching placebo and followed for about five years to capture major cardiovascular outcomes such as myocardial infarction, stroke, and cardiovascular death. Key exclusion criteria include type 1 diabetes, a major cardiac event within 60 days before screening, and NYHA Class IV heart failure. The primary analysis will compare the incidence of predefined cardiovascular events between the treatment arms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have established ASCVD and/or CKD

Exclusion Criteria:

* Have type 1 diabetes
* Have had a major heart condition within 60 days prior to screening
* Have New York Heart Association Functional Classification Class IV heart failure

Where it's running

• Instituto de Investigaciones Clínicas Bahia Blanca
  Bahía Blanca, Argentina Recruiting
• CONEXA Investigacion Clinica S.A.
  Buenos Aires, Argentina Recruiting
• Buenos Aires Macula S.A
  Buenos Aires, Argentina Recruiting
• Ciprec
  Buenos Aires, Argentina Recruiting
• Instituto Médico Especializado (IME)
  Buenos Aires, Argentina Recruiting
• Cicemo Srl
  Buenos Aires, Argentina Recruiting

+516 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observational look at how Kremezin works in adults with advanced chronic kidney disease

  This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.

  Recruiting HK inno.N Corporation · Seoul · NCT07930169

• Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China

  This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 4 Novo Nordisk A/S · Fuyang, Anhui and 25 other locations · NCT07900438

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa

  This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.

  Recruiting University of Eastern Finland · Savonlinna · NCT07820800

• Understanding heart artery disease using biomarkers and imaging in Oxford

  Researchers in Oxford are testing how biomarkers and advanced imaging can help explain why some heart artery plaques are unstable and how this affects heart damage after a heart attack.

  Recruiting University of Oxford · Oxford · NCT07772570

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.